- Home
- Publications
- Publication Search
- Publication Details
Title
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume -, Issue -, Pages -
Publisher
Massachusetts Medical Society
Online
2023-06-05
DOI
10.1056/nejmoa2301665
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
- (2023) Jason R. Westin et al. CLINICAL CANCER RESEARCH
- CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
- (2022) Jason Westin et al. BLOOD
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
- (2022) Sattva S. Neelapu et al. NATURE MEDICINE
- Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
- (2022) Mahmoud Elsawy et al. BLOOD
- Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
- (2022) Frederick L. Locke et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
- (2022) Matthew A. Lunning et al. BLOOD
- CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- (2022) Sarah M. Larson et al. Cancer Discovery
- Diffuse Large B-Cell Lymphoma
- (2021) Laurie H. Sehn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy
- (2021) Hao Ren et al. Frontiers in Immunology
- Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
- (2021) Koji Kato et al. International Journal of Clinical Oncology
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- (2021) Michael R. Bishop et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
- (2020) Jennifer M. Logue et al. HAEMATOLOGICA
- Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
- (2020) Paolo Strati et al. HAEMATOLOGICA
- Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
- (2020) Frederick L. Locke et al. Blood Advances
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
- (2017) Gustaaf W. van Imhoff et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- (2015) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started